216 related articles for article (PubMed ID: 32975815)
1. Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.
Feldman DR; Ged Y; Lee CH; Knezevic A; Molina AM; Chen YB; Chaim J; Coskey DT; Murray S; Tickoo SK; Reuter VE; Patil S; Xiao H; Aghalar J; Apollo AJ; Carlo MI; Motzer RJ; Voss MH
Cancer; 2020 Dec; 126(24):5247-5255. PubMed ID: 32975815
[TBL] [Abstract][Full Text] [Related]
2. Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.
Voss MH; Molina AM; Chen YB; Woo KM; Chaim JL; Coskey DT; Redzematovic A; Wang P; Lee W; Selcuklu SD; Lee CH; Berger MF; Tickoo SK; Reuter VE; Patil S; Hsieh JJ; Motzer RJ; Feldman DR
J Clin Oncol; 2016 Nov; 34(32):3846-3853. PubMed ID: 27601542
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients.
Choi Y; Keam B; Kim M; Yoon S; Kim D; Choi JG; Seo JY; Park I; Lee JL
Cancer Res Treat; 2019 Oct; 51(4):1549-1556. PubMed ID: 30913859
[TBL] [Abstract][Full Text] [Related]
4. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.
Escudier B; Molinie V; Bracarda S; Maroto P; Szczylik C; Nathan P; Negrier S; Weiss C; Porta C; Grünwald V; Albiges L
Eur J Cancer; 2016 Dec; 69():226-235. PubMed ID: 27680407
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
[TBL] [Abstract][Full Text] [Related]
6. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.
Ravaud A; Barrios CH; Alekseev B; Tay MH; Agarwala SS; Yalcin S; Lin CC; Roman L; Shkolnik M; Anak O; Gogov S; Pelov D; Louveau AL; Melichar B
Ann Oncol; 2015 Jul; 26(7):1378-84. PubMed ID: 25851632
[TBL] [Abstract][Full Text] [Related]
7. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.
Hutson TE; Michaelson MD; Kuzel TM; Agarwal N; Molina AM; Hsieh JJ; Vaishampayan UN; Xie R; Bapat U; Ye W; Jain RK; Fishman MN
Eur Urol; 2021 Aug; 80(2):162-170. PubMed ID: 33867192
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma.
Koh Y; Lim HY; Ahn JH; Lee JL; Rha SY; Kim YJ; Kim TM; Lee SH
Ann Oncol; 2013 Apr; 24(4):1026-31. PubMed ID: 23180114
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
Voss MH; Bastos DA; Karlo CA; Ajeti A; Hakimi AA; Feldman DR; Hsieh JJ; Molina AM; Patil S; Motzer RJ
Ann Oncol; 2014 Mar; 25(3):663-668. PubMed ID: 24458473
[TBL] [Abstract][Full Text] [Related]
10. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.
Gao X; Jegede O; Gray C; Catalano PJ; Novak J; Kwiatkowski DJ; McKay RR; George DJ; Choueiri TK; McDermott DF; Signoretti S; Bhatt RS
Clin Genitourin Cancer; 2018 Oct; 16(5):341-348. PubMed ID: 29754934
[TBL] [Abstract][Full Text] [Related]
12. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.
McGregor BA; McKay RR; Braun DA; Werner L; Gray K; Flaifel A; Signoretti S; Hirsch MS; Steinharter JA; Bakouny Z; Flippot R; Wei XX; Choudhury A; Kilbridge K; Freeman GJ; Van Allen EM; Harshman LC; McDermott DF; Vaishampayan U; Choueiri TK
J Clin Oncol; 2020 Jan; 38(1):63-70. PubMed ID: 31721643
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
Tykodi SS; Gordan LN; Alter RS; Arrowsmith E; Harrison MR; Percent I; Singal R; Van Veldhuizen P; George DJ; Hutson T; Zhang J; Zoco J; Johansen JL; Rezazadeh Kalebasty A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210307
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Gleeson JP; Nikolovski I; Dinatale R; Zucker M; Knezevic A; Patil S; Ged Y; Kotecha RR; Shapnik N; Murray S; Russo P; Coleman J; Lee CH; Stadler ZK; Hakimi AA; Feldman DR; Motzer RJ; Reznik E; Voss MH; Chen YB; Carlo MI
Clin Cancer Res; 2021 May; 27(10):2910-2919. PubMed ID: 33658299
[TBL] [Abstract][Full Text] [Related]
15. Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma.
Lee CH; Motzer RJ; Glen H; Michaelson MD; Larkin J; Minoshima Y; Kanekiyo M; Ikezawa H; Sachdev P; Dutcus CE; Funahashi Y; Voss MH
Br J Cancer; 2021 Jan; 124(1):237-246. PubMed ID: 33024271
[TBL] [Abstract][Full Text] [Related]
16. Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.
Merchan JR; Qin R; Pitot H; Picus J; Liu G; Fitch T; Maples WJ; Flynn PJ; Fruth BF; Erlichman C
Cancer Chemother Pharmacol; 2015 Mar; 75(3):485-93. PubMed ID: 25556030
[TBL] [Abstract][Full Text] [Related]
17. MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features.
Denize T; Just PA; Sibony M; Blons H; Timsit MO; Drossart T; Jakubowicz D; Broudin C; Morini A; Molina T; Vano Y; Auvray-Kuentz M; Richard S; Mejean A; Gimenez Roqueplo AP; Burnichon N; Verkarre V
Mod Pathol; 2021 Mar; 34(3):647-659. PubMed ID: 32770124
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).
Motzer RJ; Alyasova A; Ye D; Karpenko A; Li H; Alekseev B; Xie L; Kurteva G; Kowalyszyn R; Karyakin O; Neron Y; Cosgriff T; Collins L; Brechenmacher T; Lin C; Morgan L; Yang L
Ann Oncol; 2016 Mar; 27(3):441-8. PubMed ID: 26681676
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Motzer RJ; Escudier B; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Plimack ER; Procopio G; McDermott DF; Castellano D; Choueiri TK; Donskov F; Gurney H; Oudard S; Richardet M; Peltola K; Alva AS; Carducci M; Wagstaff J; Chevreau C; Fukasawa S; Tomita Y; Gauler TC; Kollmannsberger CK; Schutz FA; Larkin J; Cella D; McHenry MB; Saggi SS; Tannir NM
Cancer; 2020 Sep; 126(18):4156-4167. PubMed ID: 32673417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
